Category

• Pipeline2

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• FDA2
• Stargardt Disease2
• Clinical Trials2
• Gene Therapy2
• Retina2
• Inherited Retinal Disease1
• Injections1

• Organizations: AAVantgarde Bio✕

Clear all

Pipeline

FDA grants Fast Track designation to AAVantgarde's Stargardt gene therapy

Status benefits clinical study of AAVB-039, an AAV8 intended to address the disease’s root cause by delivering the full-length ABCA4 gene via a single subretinal injection.

Pipeline

FDA OKs AAVantgarde's IND for Stargardt gene therapy trial

Clearance enables initiation of FIH study on AAVB-039, an AAV8 that delivers the full-length ABCA4 gene to address the disease’s root cause—enabling treatment for all types.